Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?
Belmont
H M
HM
Department for Rheumatology, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003, USA. belmont@is2.nyu.edu
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008181:Lupus Nephritis / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone